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Abstract At one level, obesity is clearly a problem of simple
physics, a result of eating too much and not expending enough
energy. The more complex question, however, is why do some
people eat more than others? Studies of human and mouse
genetics over the past two decades have uncovered a number
of pathways within the brain that play a key role in the control
of food intake. A prime example is the leptin–melanocortin
pathway, which we now know greatly contributes to mamma-
lian appetitive behaviour. However, genetic disruption of this
pathway remains rare and does not represent the major burden
of the disease that is carried by those of us with ‘common
obesity’. In recent years, genome-wide association studies
have revealed more than 100 different candidate genes linked
to BMI, with most (including many components of the
melanocortin pathway) acting in the central nervous system
and influencing food intake. So while severe disruption of the
melanocortin pathway results in severe obesity, subtle varia-
tions in these genes influence where you might sit in the normal
distribution of BMI. As we now enter this ‘post-genomics’
world, can this new information influence our treatment and
management of obese patients?
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Introduction
Obesity is arguably the greatest public health threat of the 21st
century. Its prevalence has increased dramatically over the past
three decades in almost all developed economies, and it is be-
coming a significant burden in many other emerging economies.
It isn’t only obesity that is the issue, but also the accompanying
host of comorbidities, such as type 2 diabetes, cardiovascular
disease, hypertension and certain cancers, which serve to amplify
and exacerbate the problem. While our changing lifestyle and
environment has undoubtedly driven the increase in obesity,
there remains a large variation in the response to this
‘obesogenic’ environment. There is a powerful genetic compo-
nent that underlies this variation, as revealed by its correlation
with BMI (weight in kg/height in m2) in twin and adoption
studies. These studies demonstrate that the heritability of fatmass
is between 30% and 70% [1, 2]. As a consequence, genetic
approaches can be leveraged to help characterise the underpin-
ning physiological and molecular mechanisms controlling food
intake and body weight, allowing us to understand how these
may differ between lean and obese individuals.
Over the last 20 years, studies of human and mouse genet-
ics have uncovered a number of pathways within the brain that
play a key role in the control of food intake (reviewed in [3]).
Of these, the best characterised mechanism is the hypothalam-
ic leptin–melanocortin signalling pathway, which we now
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know greatly contributes to mammalian appetitive behaviour
[4]. The vast majority of monogenic disorders that result in
severe obesity in both mouse and man involve genetic disrup-
tion of this pathway [3].
There are two ‘old dogs’ that drive the narrative of this
review; the first one is allegorical and represents the
melanocortin pathway (Fig. 1), while the second refers to a
study on the genetics of obesity in actual dogs. Here, I will
briefly chart the history of the melanocortin pathway in energy
homeostasis and then highlight some contemporary studies
that reveal ‘new tricks’ emanating from the ‘old dog’. I will
then discuss how these rare genetic disorders that result in
severe obesity have been able to inform more common forms
of obesity, and explore whether this new information can in-
fluence our treatment and management of obese patients.
Old dog: the leptin–melanocortin pathway
The discovery of leptin in 1994 [5] heralded the modern era of
genetic and mechanistic obesity studies, providing the first di-
rect evidence for a feedback loop, of sorts, that could control
food intake. In 1997 came the first report that two young cous-
ins with severe early onset obesity harboured mutations in the
gene encoding leptin (LEP), confirming that this system was
relevant across mammalian species [6]. Leptin is secreted by
white adipose tissue and is a key indicator of fat mass. This led
many to assume that leptin was a ‘satiety factor’, existing to let
the brain know when there was too much fat and, thus, when to
stop eating. In fact, the moniker ‘leptin’ comes from the Greek
term ‘leptos’, meaning thin. In 1999 came what appeared to be
the proof of this hypothesis: the reported dramatic reversal of
obesity in congenital leptin-deficient children that were treated
daily with recombinant leptin [7]. In the intervening years,
however, it has become clear that while patients with leptin
deficiency are exceptionally sensitive to leptin administration,
anyone with an intact system will not respond to leptin, certain-
ly with regards to food intake and loss of bodyweight [8]. We
now know that leptin is not a satiety signal, but rather a signal of
starvation [9]. For the vast majority of us, leptin acts in the
background, letting our brain know how much fat we are car-
rying, which is a critical piece of information because how
much fat we have is, put simply, reflective of how long we
would survive without food. Adding more exogenous leptin
changes little because we still have a surfeit of fat. However,
in times of starvation when fat levels plummet, leptin levels
drop as well, turning on the starvation response [9].
The melanocortin pathway is one of the key effector mecha-
nisms of leptin signalling in the brain (Fig. 1). The central and
eponymous component to the pathway is pro-opiomelanocortin
(POMC), which undergoes extensive post-translational process-
ing to generate a range of smaller biologically active
melanocortin peptides, as well asβ-endorphin andβ-lipotrophin.
The melanocortin peptides are agonists for five melanocortin
receptors, melanocortin 1 receptor (MC1R) to –MC5R, through
which they mediate many different functions (reviewed in [3,
4]); melanocortin peptide signalling through the MC4R plays a
key role in energy homeostasis. Indeed, both Pomc/POMC-defi-
cient mice [10] and humans [11] develop hyperphagia and obe-
sity, and genetic deletion of Mc4r/MC4R in mice [12] and
humans [13, 14] results in severe hyperphagic obesity. In fact,
to this day MC4R mutations remain the most common mono-
genic form of obesity, with pathogenic mutations found in up to
5% of cases of severe childhood obesity [15] and up to 1% of the
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Fig. 1 The old dog. POMC undergoes extensive post-translational process-
ing to generate a range of smaller biologically active melanocortin peptides.
Melanocortin signalling through MCR4 plays a key role in energy homeo-
stasis. Disruption of the leptin–melanocortin pathway results in severe obesity
in humans and mice. Existence of a human monogenic obesity syndrome or
an obesemousemodel is illustratedwith an ‘obeseman’ or an ‘obesemouse’.
Lines ending in a circle indicate antagonism at a receptor. AgRP, agouti
related peptide; CPE, carboxypeptidase E; PC1, prohormone convertase 1
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general population with a BMI >30 kg/m2 [16]. In particular, the
degree of receptor dysfunction (as measured by in vitro assays)
can be used to predict the amount of food eaten by the patient
harbouring that particular mutation during a test meal [15].
New tricks for POMC
In recent years, new findings have emerged to provide an
increasingly more nuanced view of the melanocortin pathway
and of POMC in particular. Some of these findings are
outlined in Fig. 2 and discussed in more detail in this section.
Fat Labradors (Flabradors) The investigation of humans
with POMC mutations that result in specific dysregulation of
β-melanocyte-stimulating hormone (MSH) [17, 18] suggests
that β-MSH is important for controlling food intake and body
weight in man. However, although many of the mechanistic
details regarding melanocortin signalling were elucidated using
rodent models, rodents lack the proximal dibasic cleavage site
necessary for the production of β-MSH. Thus, the in vivo study
of the role of β-MSH in appetitive behaviour has been, until
recently, quite limited. As an alternative to rodent models, dogs
that carry a 14 bp deletion in POMC, which disrupts only the β-
MSH and β-endorphin coding sequences [19], represent a
‘clean’ model of β-MSH/β-endorphin deficiency and thus pro-
vide an ideal opportunity to study the role of these hormones in
feeding behaviour.
All dogs descend from the greywolf and were domesticated
some 12,000–20,000 years ago. Modern dog breeds, however,
originated only relatively recently from a small number of
founder animals. Because of this ‘bottlenecking’ phenomenon,
dissecting the genetic basis of canine traits is more amenable
than in other more outbred species, such as humans [20]. We
have been interested in studying the genetics of obesity in dogs
and began with Labrador Retrievers, which are more food-
motivated than other breeds [21]. We found that 20% of
Labradors were heterozygous and 2% were homozygous for
the 14 bp deletion in POMC and that this mutation is associ-
ated with greater food motivation and increased body weight
[19]. In addition to Labradors, 38 other dog breeds were also
screened for this mutation, but it was only found in the closely
related Flat-Coated Retriever, in which it was also associated
with increased adiposity and food motivation [19] .
What is particularly intriguing is that while 22% of pet
Labradors carried the POMC deletion in our study, 80% of
Labradors that become guide dogs also have the deletion.
Because guide dogs are essentially responsible for a human
life, they are very highly selected for temperament and train-
ability, and ‘positive reinforcement’with food rewards plays a
key role during training. We found the allelic frequency at the
POMC locus to be significantly out of Hardy–Weinberg equi-
librium in guide dog breeding stocks, supporting our hypoth-
esis that dogs carrying the POMC deletion may be more likely
to be selected [19]. Thus, although we began the study to
understand the genetics of obesity and food motivation, we
have also begun to uncover tantalising clues about other more
complex traits, those of temperament and trainability.
POMC epigenetics Another ‘new trick’ has emerged from
two reports from Krude’s group, providing evidence that the
risk for common diseases may also depend on variation in epi-
genetic marks at specific loci of the POMC gene [22, 23]. In an
initial study in 2012, Kühnen and colleagues identified two
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Fig. 2 New tricks. Recent findings in POMC biology have demonstrated
that: (1) partial deletion of POMC results in obesity in Labrador Retrievers
because of increased food motivation [19]; (2) hypermethylation at the
POMC locus and thus lowering of melanocortinergic tone, is associated
with obesity [22, 23]; and (3) human POMCdeficiencymay be treated with
setmelanotide, an MC4R agonist, resulting in reduced food intake [24]
Diabetologia
CpG islands at the POMC locus and determined their methyla-
tion status in lean and obese children. They found that there was
a significant increase in the methylation of CpGs at the intron
2/exon 3 boundary of the POMC gene in obese children vs lean
children [22]. This hypermethylation at exon 3 interferes with
the binding of the p300 transcriptional enhancer, resulting in
reduced expression of POMC. This was the first DNA methyl-
ation variant to be associated with the risk for obesity. In a
second study, the same group showed that methylation in a
variably methylated region (VMR) in POMC, as opposed to
individual CpGs, was strongly associated with individual
BMI. They found that multiple factors could trigger POMC
VMR methylation in the early embryo and that BMI is directly
related to the level of methylation as a continuous trait [23].
While these findings have emerged from the same group and
thus have yet to be replicated, conceptually, increased methyl-
ation states in both cases most likely represents a more subtle
lowering of melanocortinergic tone, therefore linking it to an
appropriately subtle increase in BMI. These findings are con-
sistent with the previously mentioned finding that the magni-
tude of MC4R dysfunction can predict food intake at an ad
libitum test meal [15], emphasising that the melanocortin sys-
tem does not act in a binary on/off fashion but as a rheostat.
Treatment of POMC deficiency Aside for treatments for
leptin deficiency, there have been no effective pharmacological
agents available for the hyperphagia and obesity that
characterises the deficiency in melanocortin signalling; that is,
until this year. In an investigator-initiated, open-label study,
Kühnen and colleagues, in collaboration with Rhythm
Pharmaceuticals, treated two POMC-deficient patients with
setmelanotide, a new MC4R agonist [24]. The patients demon-
strated a sustained reduction in hyperphagia and dramatic
weight loss (Patient 1: 51.0 kg after 42 weeks; Patient 2:
20.5 kg after 12 weeks). This degree of pharmaceutically in-
duced weight loss has not been seen since leptin-deficient chil-
dren were first treated with leptin [7] and, hence, these findings
have energised the field. Given the role of MC4R signalling in
the modulation of blood pressure [25], the main issue with use
of previous MC4R agonists has always been the accompanying
increase in blood pressure, which is clearly not ideal in obese
patients. Setmelanotide, however, appears to achieve its effects
on food intake and weight loss without the pressor effects [24]
for reasons that are yet to be determined. However, since the
dramatic reduction of food intake by patients indicates a pow-
erful central effect, one could perhaps speculate that this com-
pound only reaches the medial basal hypothalamus, where ap-
petite is primarily regulated [3], and does not affect areas of the
brain where blood pressure is regulated. Despite the beneficial
outcomeswith setmelanotide use, however, therewas a substan-
tial darkening of skin pigmentation and hair colour in the two
patients that indicated measurable activation of the peripheral
MC1Rs [24] and a potential for increased risk of skin cancer.
Nonetheless, the benefits undoubtedly outweigh the risks for the
two POMC-deficient patients, who are still both being
scrutinised very closely indeed, in this ongoing study.
The successful use of setmelanotide has opened doors for
clinical trials of treatments for other monogenic deficiencies
of the leptin–melanocortin pathway, such asMC4R-deficiency
(which occurs in a far larger cohort than POMC deficiency)
and leptin receptor deficiency the sufferers of which, for ob-
vious reasons, are resistant to leptin treatment. These studies
are currently ongoing, and we in the field are eagerly awaiting
the results. The eventual goal is clearly to trial setmelanotide
for the treatment of more common forms of obesity. Before
this happens, however, its mechanisms of action, both central
and peripheral, will need to be defined in more detail.
Complex simplicity
What about common polygenic obesity then? It has been near-
ly 10 years since the first obesity genome-wide association
studies (GWAS) were published [26], with many more being
published in the intervening period (reviewed in [27]). Was it
worth the investment? Are we getting any closer to revealing
the underlying biology of obesity?
After the initial hype and over-expectation, which was
followed by the inevitable negativity and swing in the oppo-
site direction, the dust has now settled sufficiently to allow a
cold hard look at the information on common obesity that has
been provided by GWAS. While knowledge of actual mecha-
nisms is still thin on the ground, a surprisingly cogent narra-
tive has emerged regarding the genetic architecture of com-
mon obesity: (1) the genes that lie closest to the single nucle-
otide polymorphisms (SNPs) associated with waist:hip ratio
(i.e. where your fat is deposited), tend to be primarily
expressed in fat [28]; (2) the genes that lie closest to the
SNPs associated with BMI (i.e. how much fat you have), are
primarily expressed in the central nervous system [29]. In fact,
SNPs at more than 100 robust and well-replicated loci have
now been found to influence BMI. From these SNPs, one can
generate an obesity risk score, with each SNP having a possi-
ble score of 2 (homozygous for the risk allele), 1
(heterozygous) or 0 (homozygous for the non-risk allele).
When plotted against a large enough population, the risk score
follows a normal distribution and an increasing risk score is
directly related to increasing BMI [29] (Fig. 3).
What of our central theme, our ‘old dog’? Well, a closer
look at the identities of some of these genes reveals many
members of the leptin–melanocortin pathway; amongst them
POMC andMC4R [29]. So what is clear is that while the brain
leptin–melanocortin pathway is central to mammalian food
intake control with genetic disruption resulting in extreme
obesity, subtle variations in these same genes influence an
individual’s position in the normal distribution of BMI.
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The $64 million question
As we now enter this ‘post-genomics’ world, can this new
(and not so new) genetic information that has been discussed
here influence the treatment and management of obese pa-
tients? Are we any closer to ‘precision medicine’ for obesity?
In short, the answer at the moment is ‘it depends’. For mono-
genic forms of obesity, the answer is a resounding ‘yes’. We
can now leverage genomic medicine to identify and potential-
ly treat the 1% of the population with a BMI >30 kg/m2 that
harbour genetic mutations within the leptin–melanocortin
pathway. The use of precision medicine to inform treatment
of common polygenic obesity, however, is another story en-
tirely, as the predictive value of these SNPs and risk scores are
still very poor for any given individual. This is likely because
of a combination of the small effect size, together with the thus
far unquantified broader genetic and environmental
influences.
For one thing, it is amazing that in a field that uses such
cutting edge technology, our ability to accurately and pre-
cisely measure food intake and energy expenditure on a
large scale (in tens to hundreds of thousands of people) is
still very primitive. We will have to rectify this problem if
we truly want to bring the field of nutrigenomics from the
Stone Age to the 21st century. That being said, this has not
stopped commercial entities from stepping in and offering
‘nutrigenomics’, ‘exercise genomics’, ‘personalised weight
loss plans’ and all manner of other ‘omics’-based predic-
tions. Clearly genetic technology has reached the stage
where it is no longer the limiting factor and pretty much
anybody with a genetic analyser can accurately produce
genetic information. The problem of course is in the inter-
pretation and these charlatans (that’s what they are) are
fundamentally misunderstanding the difference between
risk and prediction. However, the genie is now out of the
bottle and any of us can now pop down to our local
drugstore or click online, pay 100–200 £/$/€, and obtain
our genetic profile. This should be motivation enough for
the scientific community to get their act together and pro-
vide some real genetic interpretation for the public.
Summary
In conclusion, the fact that the leptin–melanocortin path-
way is a key controller of mammalian appetitive behaviour
is now an ‘old dog’ in this field. Yet, new research tricks
continue to allow us to obtain a deeper and more nuanced
understanding in this area. The current focus of pharmaco-
logical therapies is aimed at individuals with deficiencies in
the leptin–melanocortin pathway (see text box: summary).
However, genetic disruption of this pathway still remains
rare, whereas the majority of individuals suffer from ‘com-
mon obesity’, which represents the major public health
threat. Therefore, while we have made enormous strides
in our understanding of the mechanisms controlling food
intake and body weight, further advances must be urgently
made to enable the optimal management and treatment of
common obesity.
Summary
Old dog:
The leptin–melanocortin signalling pathway 
greatly contributes to mammalian appetitive 
behaviour
Deficiency of POMC (which is processed to 
produce melanocortin peptides) and its recep-
tor, MC4R, result in hyperphagia and obesity
New tricks:
Flabradors: Labradors with Pomc mutations 
that disrupt β-MSH and β-endorphin coding 
sequences are more obese and food motivated
Epigenetics: Changes in methylation of specific 
regions of the POMC locus impacts on obestiy 
risk
Treatment of obesity:
Stemelanotide, a MC4R agonist, can reduce 
hyperphagia and induce weight loss in POMC-
deficient patients
What about common obesity? GWAS have 
identified SNPs associated with BMI, many of 
which lie close to leptin–melanocortin pathway 
genes. However, more work will need to be 
done before this genetic information can be 
used for personalised treatment of obesity
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Fig. 3 Obesity risk score is directly related to BMI in the population.
Schematic figure illustrating that an obesity risk score calculated using
GWAS-identified SNPs is directly related to BMI (in red). The frequency
(in purple) of obesity risk score increases from left to right, following the
normal distribution in the population
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